// App-Quantinova.ai

TCT-79 : What Biomarker Threshold for Periprocedural Myocardial Infarction Following PCI and CABG in Left Main Disease is Prognostically Relevant? Analysis from the EXCEL Trial

Researchers

Presenter

  • Shmuel Chen

Principal Investigators

  • Ori Ben-Yehuda

  • Thomas McAndrew

  • Ioanna Kosmidou

  • Bjorn Redfors

  • Marie-Claude Morice

  • David Kandzari

  • Adrian Banning

  • Ovidiu Dressler

  • Martin Leon

  • A. Pieter Kappetein

  • Joseph Sabik

  • Patrick Serruys

  • Gregg Stone

Medical Centers

  • Piedmont Heart Institute, Atlanta, Georgia, United States

  • Department of Thoracic and Cardiovascular Surgery, The Cleveland Clinic Foundation, Cleveland, Ohio, United States

  • John Radcliffe Hospital, Oxford, United Kingdom.

  • CRF, New York, New York, United States

  • Department of Cardiothoracic Surgery, Erasmus University Medical Center, Rotterdam, Netherlands

  • CERC, Massy, France

  • Cardiovascular Research Foundation, New York, New York, United States

  • Cardiovascular Research Foundation, Columbia University Medical Center/NewYork-Presbyterian Hospital, New York, New York, United States

  • Imperial College, London, United Kingdom

  • Columbia University Medical Center and Cardiovascular Research Foundation, New York, New York, United States

Locations

  • United States

  • Netherlands

  • France

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Cardiovascular (CVS)

Disease

  • Myocardial infarction

  • Left main disease

Biomarkers

  • N/A

Drug/Treatment

  • Everolimus

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved